Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Growth 2022-2028
Biologics for the prevention of reproductive and respiratory syndrome in pigs
The global market for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live players cover Yongshun Creatures, Pfizer, Boehringer Ingelheim, Bayer and Elanco, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market, with both quantitative and qualitative data, to help readers understand how the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Box.
Market Segmentation:
The study segments the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market and forecasts the market size by Kinds (TJM-F92 Strain, GDr180 Strain and JXA1-R Strain), by Downstream (Farms and Individual.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by kinds
TJM-F92 Strain
GDr180 Strain
JXA1-R Strain
Other
Segmentation by downstream
Farms
Individual
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Yongshun Creatures
Pfizer
Boehringer Ingelheim
Bayer
Elanco
MSD
Cahic
Ringpu
Baoling
Jizhong
Dahuanong
Hayao
Pulike Biology
Tecon
Sinovet
Chapter Introduction
Chapter 1: Scope of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Research Methodology, etc.
Chapter 2: Executive Summary, global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market size (sales and revenue) and CAGR, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market size by region, by kinds, by downstream, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by kinds, and kinds.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market size forecast by region, by country, by kinds, and downstream.
Chapter 13: Comprehensive company profiles of the leading players, including Yongshun Creatures, Pfizer, Boehringer Ingelheim, Bayer, Elanco, MSD, Cahic, Ringpu and Baoling, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country/Region, 2017, 2022 & 2028
2.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Kinds
2.2.1 TJM-F92 Strain
2.2.2 GDr180 Strain
2.2.3 JXA1-R Strain
2.2.4 Other
2.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds
2.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2022)
2.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue and Market Share by Kinds (2017-2022)
2.3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Kinds (2017-2022)
2.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Downstream
2.4.1 Farms
2.4.2 Individual
2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream
2.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Market Share by Downstream (2017-2022)
2.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue and Market Share by Downstream (2017-2022)
2.5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Downstream (2017-2022)
3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Company
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Breakdown Data by Company
3.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales by Company (2020-2022)
3.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Company (2020-2022)
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue by Company (2020-2022)
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Company (2020-2022)
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Company (2020-2022)
3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Company
3.4 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Location Distribution
3.4.2 Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Geographic Region
4.1 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Geographic Region (2017-2022)
4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue by Geographic Region
4.2 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country/Region (2017-2022)
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales by Country/Region (2017-2022)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue by Country/Region
4.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth
4.4 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth
4.5 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth
4.6 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth
5 Americas
5.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country
5.1.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022)
5.1.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022)
5.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds
5.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region
6.1.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2017-2022)
6.1.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2017-2022)
6.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds
6.3 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country
7.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022)
7.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022)
7.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds
7.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country
8.1.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022)
8.1.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022)
8.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds
8.3 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
10.3 Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
10.4 Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors
11.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customer
12 World Forecast Review for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Geographic Region
12.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Forecast by Region
12.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecast by Region (2023-2028)
12.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecast by Kinds
12.7 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecast by Downstream
13 Key Players Analysis
13.1 Yongshun Creatures
13.1.1 Yongshun Creatures Company Information
13.1.2 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.1.3 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Yongshun Creatures Main Business Overview
13.1.5 Yongshun Creatures Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.2.3 Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Boehringer Ingelheim
13.3.1 Boehringer Ingelheim Company Information
13.3.2 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.3.3 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Boehringer Ingelheim Main Business Overview
13.3.5 Boehringer Ingelheim Latest Developments
13.4 Bayer
13.4.1 Bayer Company Information
13.4.2 Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.4.3 Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Bayer Main Business Overview
13.4.5 Bayer Latest Developments
13.5 Elanco
13.5.1 Elanco Company Information
13.5.2 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.5.3 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Elanco Main Business Overview
13.5.5 Elanco Latest Developments
13.6 MSD
13.6.1 MSD Company Information
13.6.2 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.6.3 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 MSD Main Business Overview
13.6.5 MSD Latest Developments
13.7 Cahic
13.7.1 Cahic Company Information
13.7.2 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.7.3 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Cahic Main Business Overview
13.7.5 Cahic Latest Developments
13.8 Ringpu
13.8.1 Ringpu Company Information
13.8.2 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.8.3 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Ringpu Main Business Overview
13.8.5 Ringpu Latest Developments
13.9 Baoling
13.9.1 Baoling Company Information
13.9.2 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.9.3 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Baoling Main Business Overview
13.9.5 Baoling Latest Developments
13.10 Jizhong
13.10.1 Jizhong Company Information
13.10.2 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.10.3 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Jizhong Main Business Overview
13.10.5 Jizhong Latest Developments
13.11 Dahuanong
13.11.1 Dahuanong Company Information
13.11.2 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.11.3 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Dahuanong Main Business Overview
13.11.5 Dahuanong Latest Developments
13.12 Hayao
13.12.1 Hayao Company Information
13.12.2 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.12.3 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Hayao Main Business Overview
13.12.5 Hayao Latest Developments
13.13 Pulike Biology
13.13.1 Pulike Biology Company Information
13.13.2 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.13.3 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Pulike Biology Main Business Overview
13.13.5 Pulike Biology Latest Developments
13.14 Tecon
13.14.1 Tecon Company Information
13.14.2 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.14.3 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Tecon Main Business Overview
13.14.5 Tecon Latest Developments
13.15 Sinovet
13.15.1 Sinovet Company Information
13.15.2 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
13.15.3 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Sinovet Main Business Overview
13.15.5 Sinovet Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of TJM-F92 Strain
Table 4. Major Players of GDr180 Strain
Table 5. Major Players of JXA1-R Strain
Table 6. Major Players of Other
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2022)
Table 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & ($ million)
Table 10. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2022)
Table 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Kinds (2017-2022) & (US$/Box)
Table 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2022)
Table 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022)
Table 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream (2017-2022)
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Downstream (2017-2022) & (US$/Box)
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Company (2020-2022) & (Box)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Company (2020-2022)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Company (2020-2022)
Table 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Company (2020-2022) & (US$/Box)
Table 22. Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Producing Area Distribution and Sales Area
Table 23. Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
Table 24. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Geographic Region (2017-2022) & (Box)
Table 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share Geographic Region (2017-2022)
Table 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country/Region (2017-2022) & (Box)
Table 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country/Region (2017-2022)
Table 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 36. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2017-2022)
Table 37. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2017-2022)
Table 39. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2017-2022) & (Box)
Table 40. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2022)
Table 41. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 42. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2022)
Table 43. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2017-2022) & (Box)
Table 44. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2017-2022)
Table 45. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2017-2022)
Table 47. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 48. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2022)
Table 49. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 50. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2022)
Table 51. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 52. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2017-2022)
Table 53. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2017-2022)
Table 55. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2017-2022) & (Box)
Table 56. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2022)
Table 57. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 58. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2022)
Table 59. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 60. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 64. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2022)
Table 65. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 66. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Table 68. Key Market Challenges & Risks of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Table 69. Key Industry Trends of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Table 70. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors List
Table 73. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customer List
Table 74. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Region (2023-2028) & (Box)
Table 75. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Forecast by Region
Table 76. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Country (2023-2028) & (Box)
Table 79. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Region (2023-2028) & (Box)
Table 81. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Country (2023-2028) & (Box)
Table 83. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Country (2023-2028) & (Box)
Table 85. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Kinds (2023-2028) & (Box)
Table 87. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share Forecast by Kinds (2023-2028)
Table 88. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Kinds (2023-2028) & ($ Millions)
Table 89. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share Forecast by Kinds (2023-2028)
Table 90. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Forecast by Downstream (2023-2028) & (Box)
Table 91. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share Forecast by Downstream (2023-2028)
Table 92. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Forecast by Downstream (2023-2028) & ($ Millions)
Table 93. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share Forecast by Downstream (2023-2028)
Table 94. Yongshun Creatures Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 95. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 96. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 97. Yongshun Creatures Main Business
Table 98. Yongshun Creatures Latest Developments
Table 99. Pfizer Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 100. Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 101. Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 102. Pfizer Main Business
Table 103. Pfizer Latest Developments
Table 104. Boehringer Ingelheim Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 105. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 106. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 107. Boehringer Ingelheim Main Business
Table 108. Boehringer Ingelheim Latest Developments
Table 109. Bayer Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 110. Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 111. Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 112. Bayer Main Business
Table 113. Bayer Latest Developments
Table 114. Elanco Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 115. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 116. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 117. Elanco Main Business
Table 118. Elanco Latest Developments
Table 119. MSD Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 120. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 121. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 122. MSD Main Business
Table 123. MSD Latest Developments
Table 124. Cahic Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 125. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 126. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 127. Cahic Main Business
Table 128. Cahic Latest Developments
Table 129. Ringpu Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 130. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 131. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 132. Ringpu Main Business
Table 133. Ringpu Latest Developments
Table 134. Baoling Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 135. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 136. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 137. Baoling Main Business
Table 138. Baoling Latest Developments
Table 139. Jizhong Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 140. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 141. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 142. Jizhong Main Business
Table 143. Jizhong Latest Developments
Table 144. Dahuanong Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 145. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 146. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 147. Dahuanong Main Business
Table 148. Dahuanong Latest Developments
Table 149. Hayao Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 150. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 151. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 152. Hayao Main Business
Table 153. Hayao Latest Developments
Table 154. Pulike Biology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 155. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 156. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 157. Pulike Biology Main Business
Table 158. Pulike Biology Latest Developments
Table 159. Tecon Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 160. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 161. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 162. Tecon Main Business
Table 163. Tecon Latest Developments
Table 164. Sinovet Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base, Sales Area and Its Competitors
Table 165. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 166. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue ($ Million), Price (US$/Box) and Gross Margin (2020-2022)
Table 167. Sinovet Main Business
Table 168. Sinovet Latest Developments
List of Figures
Figure 1. Picture of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Figure 2. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth Rate 2017-2028 (Box)
Figure 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of TJM-F92 Strain
Figure 10. Product Picture of GDr180 Strain
Figure 11. Product Picture of JXA1-R Strain
Figure 12. Product Picture of Other
Figure 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds in 2021
Figure 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2022)
Figure 15. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Consumed in Farms
Figure 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market: Farms (2017-2022) & (Box)
Figure 17. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Consumed in Individual
Figure 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market: Individual (2017-2022) & (Box)
Figure 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2022)
Figure 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream in 2021
Figure 21. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market by Company in 2021 ($ Million)
Figure 22. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Company in 2021
Figure 23. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Geographic Region in 2021
Figure 25. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2017-2022)
Figure 26. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country/Region in 2021
Figure 27. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2017-2022 (Box)
Figure 28. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2017-2022 ($ Millions)
Figure 29. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2017-2022 (Box)
Figure 30. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2017-2022 ($ Millions)
Figure 31. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2017-2022 (Box)
Figure 32. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2017-2022 (Box)
Figure 34. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2017-2022 ($ Millions)
Figure 35. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country in 2021
Figure 36. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country in 2021
Figure 37. United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region in 2021
Figure 42. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Regions in 2021
Figure 43. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 47. India Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country in 2021
Figure 50. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country in 2021
Figure 51. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 52. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country in 2021
Figure 57. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country in 2021
Figure 58. Egypt Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in 2021
Figure 64. Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Figure 65. Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets